Literature DB >> 16928361

Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat.

Yaoming Wang1, Veronica Galvan, Olivia Gorostiza, Marina Ataie, Kunlin Jin, David A Greenberg.   

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenesis factor with neurotrophic, neuroprotective and neuroproliferative effects. Depending on the dose, route and time of administration in relation to focal cerebral ischemia, VEGF can improve histological outcome and sensorimotor function in rodents. However, VEGF also increases vascular permeability, which can lead to brain edema and exacerbate ischemic brain injury. Thus, although VEGF is a candidate therapeutic for stroke and other ischemic disorders, its benefit relative to risk is uncertain. Considering that functional rather than histological measures of outcome are probably most relevant to therapeutic prospects for human stroke, we investigated the effects of VEGF after middle cerebral artery occlusion in rats using a series of behavioral tests. We report that VEGF improves functional outcome in ischemic rats, including both sensorimotor and cognitive deficiencies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928361     DOI: 10.1016/j.brainres.2006.07.060

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Perlecan domain V inhibits amyloid-β induced brain endothelial cell toxicity and restores angiogenic function.

Authors:  Christi Parham; Lisa Auckland; Jessica Rachwal; Douglas Clarke; Gregory Bix
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  VEGF ameliorates cognitive impairment in in vivo and in vitro ischemia via improving neuronal viability and function.

Authors:  Jiajia Yang; Yang Yao; Ting Chen; Tao Zhang
Journal:  Neuromolecular Med       Date:  2013-12-14       Impact factor: 3.843

3.  Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment.

Authors:  Sung Su An; Hong Lian Jin; Keung Nyun Kim; Dong Seok Kim; Joon Cho; Meng-Lu Liu; Jin Soo Oh; Do Heum Yoon; Min Hyung Lee; Yoon Ha
Journal:  Childs Nerv Syst       Date:  2010-03       Impact factor: 1.475

4.  Ginsenoside Rd promotes neurogenesis in rat brain after transient focal cerebral ischemia via activation of PI3K/Akt pathway.

Authors:  Xin-yu Liu; Xin-yu Zhou; Jin-cai Hou; Hua Zhu; Zhong Wang; Jian-xun Liu; Yong-qiu Zheng
Journal:  Acta Pharmacol Sin       Date:  2015-03-16       Impact factor: 6.150

5.  Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation.

Authors:  Thorsten R Doeppner; Britta Kaltwasser; Ayman ElAli; Anil Zechariah; Dirk M Hermann; Mathias Bähr
Journal:  J Cereb Blood Flow Metab       Date:  2010-12-01       Impact factor: 6.200

6.  Comparison of trophic factors changes in the hippocampal CA1 region between the young and adult gerbil induced by transient cerebral ischemia.

Authors:  Bing Chun Yan; Joon Ha Park; Sung Koo Kim; Jung Hoon Choi; Choong Hyun Lee; Ki-Yeon Yoo; Young-Geun Kwon; Young-Myeong Kim; Jong-Dai Kim; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.046

7.  Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections.

Authors:  Andreas Stahl; Nicolas Feltgen; Antje Fuchs; Michael Bach
Journal:  Doc Ophthalmol       Date:  2008-06-20       Impact factor: 2.379

Review 8.  Vascular endothelial growth factors (VEGFs) and stroke.

Authors:  David A Greenberg; Kunlin Jin
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

9.  Delayed VEGF treatment enhances angiogenesis and recovery after neonatal focal rodent stroke.

Authors:  M Dzietko; N Derugin; M F Wendland; Z S Vexler; D M Ferriero
Journal:  Transl Stroke Res       Date:  2013-04       Impact factor: 6.829

10.  Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients.

Authors:  Focke Ziemssen; Matthias Lüke; Andre Messias; Julia Beutel; Olcay Tatar; Eberhart Zrenner; Karl U Bartz-Schmidt
Journal:  Int Ophthalmol       Date:  2007-07-20       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.